PDF Reprint regarding RYTARY extended release sinemet drug

This new drug is something that PWPs have heard about and have been anticipating for the last year.  I am going to discuss it with my doctor this month.  In my case, I am hoping this will allow me to sleep through the night without having to worry about taking sinemet every four hours, which I currently have to do to avoid feeling "really lousy" in the morning.  I will be interested to learn about how long this "extended release" drug may be effective for me, possible side effects, cost and more.  I would encourage all interested PWPs to discuss with their doctors! The Parkinson’s Disease Foundation (PDF) alerts the community that RYTARYTM, an extended release formulation of carbidopa/levodopa, has been approved by the US Food and Drug Administration (FDA) for the treatment of Parkinson's disease.

With your support, we are funding research to solve, treat and end Parkinson’s.

FDA Approves RYTARY: What Does It Mean? PDF alerts the community that RYTARYTM, an extended release formulation of carbidopa/levodopa, has been approved by the US Food and Drug Administration (FDA) for the treatment of Parkinson's disease. The approval was announced on Thursday by the drug’s manufacturer, Impax Pharmaceuticals. Carbidopa/levodopa remains the gold-standard for easing motor symptoms. But as PD advances, the drug becomes effective for shorter time periods. This "wearing off" leads to a worsening of motor symptoms. The manufacturer of RYTARYTM states that the drug is designed to reduce these “off times” in people with Parkinson’s disease. What does it mean? See our team’s take.  Read our Statement  View our Video Parkinson's Helpline For additional information about medications for Parkinson’s disease, please contact PDF's HelpLine at (800) 457-6676 or info@pdf.org. Thank you for your support, James Beck, Ph.D., Vice President of Scientific Affairs, Parkinson’s Disease Foundation Our Commitment to Efficiency Thanks to our low administrative costs, 80% of our budget goes directly to Parkinson’s research, education and advocacy. Make a donation today to support our mission. Thank you for your generosity.